On May 27, PegBio Pharma (02565.HK) declined 15.99% in regular trading, trading at HK$8.78/share, with trading volume of HK$53.49 million.

On the news front, May 27 marks the one-year anniversary of PegBio Pharma's listing on the Hong Kong Stock Exchange, triggering the full expiry of the lock-up period for all pre-IPO shareholders. A large volume of low-cost shares became freely tradable simultaneously, creating concentrated selling pressure on the stock.

PegBio Pharma is a biotechnology company focused on chronic metabolic diseases, with its core product PB-119 being a long-acting GLP-1 receptor agonist nearing commercialization, targeting type 2 diabetes and obesity. The stock had already experienced significant weakness in recent months, falling from HK$62 to approximately HK$12.74 over the prior three months — a drawdown of nearly 80%. Analysts have flagged ongoing risks including persistent net losses, intense GLP-1 competition, and high price volatility as key concerns for the near term.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)